![]() Institutional investors, analysts and members of the media alsoĬan participate by dialing (706) 634-2289 or (877) 214-9289 and using ID There will be a live webcast of the event available on Merck’s websiteĪt Software needed to listen to the webcast may be obtained on theĬorporate website and should be downloaded prior to the beginning of the Senior management will detail the company’s research strategy, showcaseĬandidates from its research and development pipeline and provide a Merck will hold an Investor Briefing today at 9:00 a.m. Merck with ongoing portfolio assessment leading up to the transaction. LLC acted as financial advisor to Merck, and Friedįrank Harris Shriver & Jacobson LLP and Morgan Lewis & Bockius LLP actedĪs legal counsel in connection with the transaction. TheĬompany plans to update its 2014 financial guidance when the transaction To customary closing conditions, including regulatory approvals. Merck expects to close the sale of MCC in second half of 2014, subject Strengths of our team will serve Bayer well.” “The value we obtained for our consumer business is a tribute to ourĬolleagues who have built an outstanding business with a talented teamĪnd trusted, well-known product brands,” said Frazier. Respective strengths, and we look forward to working with Bayer in the “Our collaboration with Bayer builds on our “Both Merck and Bayer have a rich history of developing andĬommercializing innovative products to meet significant unmet medical Industry-leading return of capital to shareholders. Opportunities, such as MK-3475, to augment the company’s pipeline withĮxternal assets that can create value and to continue to provide an The company will use the after-tax proceeds -Ĭonsistent with its capital allocation strategy - to resource thoseĪreas within its business that represent the highest potential growth Merck expects after-tax proceeds from the sale of MCC to be between $8Īnd $9 billion. Included in the agreement, both companies will share in developmentĬosts and profits on sales and will have the right to co-promote in ![]() Vericiguat and other potential opt-in products, Bayer will lead in the Merck will lead commercialization in the rest of the world (ROW). For Adempas,īayer will continue to lead commercialization in the Americas, while Payments upon the achievement of agreed-upon sales goals. In return for these broad collaboration rights, Bayer will receive a $1īillion up-front payment with the potential for additional milestone Merck will in turn make available its early-stage (BAY102), which is currently in Phase 2 trials for worsening heartįailure, as well as opt-in rights for other early-stage sGC compounds inĭevelopment at Bayer. The collaboration also includes clinical development of vericiguat ![]() Of innovation, joining our strong Consumer Care team at Bayer We lookįorward to having the talents of the Merck team, with their track record “TheĬombination of Merck Consumer Care’s complementary portfolio of productsĪnd geographic reach with Bayer’s will create a global consumer careīusiness better positioned to serve consumers around the world. Marijn Dekkers, Bayer AG Chairman of the Board of Management. Well-established product brands, such as Claritin, Afrin andĬoppertone®, that are leaders in their respective categories,” said Dr. “Merck Consumer Care is a strong business with a portfolio of Through targeted investments that strengthen our product portfolio and Goal of being the premier research-intensive biopharmaceutical company “By unlocking value in Merck Consumer Care, we’re able to further our Frazier, chairman and chief executive officer, Merck. Industry-leading potential and generate long-term shareholder value,” That assets within our portfolio align with our core strategy, have “The sale of our consumer care business is part of our efforts to ensure ![]() The two companies will equally share costs and profitsįrom the collaboration and implement a joint development and Marketed in the United States and Europe for both PAH and CTEPH and in Thromboembolic pulmonary hypertension (CTEPH). Is approved to treat pulmonary arterial hypertension (PAH) and is theįirst and only drug treatment approved for patients with chronic (riociguat), the first member of this novel class of compounds. The company also announced a worldwide clinical developmentĬollaboration with Bayer to market and develop its portfolio of soluble Under the terms of the agreement, Bayer AG will acquire Merck’sĮxisting OTC business, including the global trademark and prescription Its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2īillion. Today announced that it has entered into a definitive agreement to sell Merck (NYSE:MRK), known as MSD outside the United States and Canada, Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular DiseaseĬollaboration Includes a $1 Billion Up-front Payment by Merck to Bayer
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |